The rarity of primary central nervous system lymphoma (PCNSL) and treatment heterogeneity contributes to a lack of prognostic models for evaluating posttreatment remission. This study aimed to develop and validate… Click to show full abstract
The rarity of primary central nervous system lymphoma (PCNSL) and treatment heterogeneity contributes to a lack of prognostic models for evaluating posttreatment remission. This study aimed to develop and validate radiomic‐based models to predict the durable response (DR) to high‐dose methotrexate (HD‐MTX)‐based chemotherapy in PCNSL patients.
Keywords:
central nervous;
nervous system;
response high;
system lymphoma;
primary central;
durable response
Journal Title: Cancer Medicine
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!
Journal Title: Cancer Medicine
Year Published: 2024
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!